WASHINGTON, Dec. 21, 2010 /PRNewswire-USNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced the election of four new members to its Board of Directors.
"We are pleased to welcome four new biopharmaceutical heavyweights to join PhRMA's Board of Directors," said PhRMA President and Chief Executive Officer John J. Castellani. "As leaders of one of the most research-intensive sectors in the U.S., they bring to the table incredible insight and a keen understanding of the challenging economic, legislative and regulatory environments the industry faces on a daily basis."
Castellani continued, "Despite these challenges, our Board of Directors has made it a top priority to build upon core patient-centered principles that guide our advocacy efforts as we work to advance public policies that foster medical innovation and help the U.S. maintain its global leadership in medical discovery. We look forward to working with all our Board members to this aim in the months and years ahead."
Ian Read was recently named President and Chief Executive Officer of Pfizer Inc. Previously, he served as Senior Vice President, Pfizer Inc., and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.
Mr. Read began his career with Pfizer in 1978 as an operational auditor. He held various positions, including Chief Financial Officer, Pfizer Mexico in Pfizer's Latin America operations. In 1996, Mr. Read was appointed President of Pfizer's International Pharmaceuticals Groups, with responsibility for Latin America and Canada. He became Executive Vice President, Europe in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition t
|SOURCE Pharmaceutical Research and Manufacturers of America|
Copyright©2010 PR Newswire.
All rights reserved